News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 06 - 11

World's First Oral Solid Microtubule Stabilizer Receives Phase III Clinical Approval! Breakthrough f

Beijing, China, June 11, 2026 — Beijing Biostar Pharmaceuticals Co., Ltd. (hereinafter referred to as "Biostar", stock code: 2563.HK), a biopharmaceutical company leveraging a synthetic biology R&D platform to focus on developing proprietary anticancer drugs, today announced that its core pipeline product, utidelone capsules (UTD2), has received clinical trial approval (Notice No.: 2026LP01769) from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III clinical study (BG02-2601) in the treatment of HER2-negative advanced breast ...

浏览次数：2

查看详情>>

发布时间: 2026 - 06 - 05

Straight to ASCO 2026 | China's Power Shines Globally, EFUNG Capital's Portfolio Companies Unveil Gr

The annual premier global academic event in oncology — the American Society of Clinical Oncology (ASCO) Annual Meeting — took place as scheduled from May 29 to June 2 local time in Chicago, USA. As one of the most influential academic gatherings in global oncology, ASCO has consistently served as the ultimate proving ground for innovative biotech companies to validate their products. The conference brings together clinicians, researchers, biopharma industry professionals, and media from around the world, spotlighting cutting-edge R&D data on novel cancer drugs and breakthrough results from...

浏览次数：4

查看详情>>

发布时间: 2026 - 05 - 29

Huayuan Regenerative Medicine's Kidney Cell Therapy Receives FDA Orphan Drug Designation

On May 27, 2026, the official website of the U.S. Food and Drug Administration (FDA) announced that ARM101 (Human Renal Progenitor Cell Injection), an hiPSC-derived nephron progenitor cell drug independently developed by Asia Regenerative Medicine Co., Ltd., has officially received Orphan Drug Designation (ODD). The designated indication is for the prevention of Delayed Graft Function (DGF) in kidney transplant recipients. This is the world's first cell therapy targeting DGF to receive FDA Orphan Drug Designation, filling an international gap in the recognition of cell therapy products for...

浏览次数：3

查看详情>>

发布时间: 2026 - 05 - 29

Monthly Health Read | May 2026

Since the beginning of 2026, China's capital markets have demonstrated remarkable resilience. In the first quarter, GDP grew 5.0% year-on-year, exceeding market expectations. Entering May, A-shares continued their strong momentum, with the Shanghai Composite Index breaking through 4,200 points to reach an 11-year high. The positive macro data and market sentiment have created a favorable window for high-quality companies to pursue capital raising and business expansion.Against this positive macro backdrop, several of Efung Capital's portfolio companies have seen intensive financing pro...

浏览次数：2

查看详情>>